5 Best Building Product Stocks To Buy For 2015

Quanex Building Products (NYSE: NX  ) reported earnings on June 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended April 30 (Q2), Quanex Building Products beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share dropped.

Margins increased across the board.

Revenue details
Quanex Building Products reported revenue of $232.5 million. The seven analysts polled by S&P Capital IQ expected revenue of $224.8 million on the same basis. GAAP reported sales were 20% higher than the prior-year quarter's $194.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.20. The eight earnings estimates compiled by S&P Capital IQ predicted -$0.08 per share. GAAP EPS were -$0.20 for Q2 against -$0.34 per share for the prior-year quarter.

5 Best Building Product Stocks To Buy For 2015: Pool Corporation (POOL)

Pool Corporation operates as a wholesale distributor of swimming pool supplies, equipment, and related leisure products in North America and Europe. The company offers approximately 100,000 national brand and Pool Corporation branded products. It sells maintenance products, such as chemicals, supplies, and pool accessories; repair and replacement parts for cleaners, filters, heaters, pumps, and lights; packaged pool kits, including walls, liners, braces, and coping for in-ground and above-ground pools; pool equipment and components for new pool construction and the remodeling of existing pools; and irrigation and landscape products, such as professional lawn care equipment. The company also offers complementary products, including building materials used for pool installations and remodeling, such as concrete, plumbing and electrical components, and pool surface and decking materials; and other discretionary recreational and related outdoor lifestyle products. Pool Corpora tion serves swimming pool remodelers and builders, retail swimming pool stores, swimming pool repair and service businesses, landscape construction and maintenance contractors, and golf courses. The company was founded in 1993 and is based in Covington, Louisiana.

Advisors' Opinion:

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Pool (Nasdaq: POOL  ) .

5 Best Building Product Stocks To Buy For 2015: BE Aerospace Inc.(BEAV)

BE Aerospace, Inc. designs, manufactures, sells, and services commercial aircraft and business jet cabin interior products worldwide. The company?s Commercial Aircraft segment offers seat frames, cushions, armrests, and tray tables; various optional features, such as adjustable lumbar supports, footrests, reading lights, head/neck supports, and other comfort amenities; oxygen storage, distribution, and delivery systems for commercial and business jet aircrafts; aircraft coffee and beverage makers, and coffee warmers and water boilers; convection, steam, and warming ovens; commercial aircraft refrigeration equipment; modular lavatory systems; vacuum waste water and galley systems; and thermal and power management solutions. This segment also offers engineering, design, integration, installation, and certification services for commercial aircraft passenger cabin interiors; in-house capabilities to design, manage, integrate, test, and certify reconfigurations and modificatio ns for commercial aircraft and to manufacture related products, including engineering kits and interface components; and interior reconfiguration services. Its Consumables Management segment provides inventory management and replenishment, electronic data interchange, special packaging and bar-coding, parts kitting, quality assurance testing, and purchasing assistance services; and creative and differential supply chain solutions, such as 3PL and 4PL programs. This segment also distributes aerospace fasteners and consumables. The company?s Business Jet segment offers a line of furnishings for business jets, including seating and sofa products, such as electric fully berthing lie flat seats, direct and indirect lighting, air valves, oxygen delivery systems, sidewalls, bulkheads, credenzas, closets, galley structures, lavatories, and tables; and super first class cabin interior products for commercial wide-body aircraft. The company was founded in 1987 and is headquartered in Wellington, Florida.

Advisors' Opinion:

• [By Rich Smith]

  This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature a pair of hikes to price target at aerospace parts suppliers B/E Aerospace (NASDAQ: BEAV  ) and Precision Castparts (NYSE: PCP  ) . But the news isn't all good, so before we address those two, let's start with why one analyst thinks...

• [By GuruFocus]

  George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

Top 10 Growth Stocks To Buy Right Now: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors' Opinion:

• [By Philip Springer]

  Just last week, the major US stock averages hit all-time highs, led by large-cap stocks, including some that had been lagging for many years. But it’s been a different story in March-April for stocks that had the biggest gains of 2013 and early this year.
  
  This week brought more bad news for the stock market’s two most overvalued sectors, biotechnology and information technology. Worse, when the paddy wagon came, as usual it took the good stocks with the bad, to rephrase an old Wall St. aphorism in politically correct terms.
  
  Yesterday, the technology-heavy Nasdaq Composite Index tumbled 3.1 percent, its �biggest one-day drop in nearly 2陆 years. This dragged the broader market sharply lower, as investors resumed selling biotechnology stocks in general and many technology stocks. As of April 10, the Nasdaq Composite was 7 percent off its 14-year high, which was reached last month. Yet the S&P 500 and Dow Jones Industrial Average remain not far from their all-time record peaks, down 3 percent and 2.5 percent respectively.
  
  There are many reasons for the decline of both the junk and the good growth stocks. First, the broad market has been long overdue for a 10 percent correction, which still hasn’t occurred.
  
  Second, the high fliers were much more overdue for a reality check. These particularly include extremely overvalued companies in social media, the “cloud,” 3d printing, biotechnology and more.
  
  Third, the new-issues market, which naturally has consisted primarily of info tech and biotech issues, created too much new supply that inevitably dampened investor demand for the more established companies in those sectors.
  
  The increased importance of trading exchange-traded funds, as both a way to invest and to hedge against market declines, inevitably adds to the downward pressure in this situation.� Reason: Shares of all of their components are sold, regardless of each stock’s relative me

• [By Keith Speights]

  Currently, the top 10 stocks in which the ETF is invested comprise more than 55% of total assets. Sure, there are some speculative names included in the full list of holdings. However, the largest stakes are in big biotechs with long track records, like Gilead Sciences (NASDAQ: GILD  ) , Celgene (NASDAQ: CELG  ) , Amgen (NASDAQ: AMGN  ) , and Biogen Idec (NASDAQ: BIIB  ) . These top four holdings make up almost one-third of the ETF's total assets.

• [By Ben Levisohn]

  Shares of Gilead Sciences has dropped 1.3% to $81.52 at 10:33 a.m., while Amgen (AMGN) has fallen 0.3% to $123.78,�Biogen Idec�(BIIB) has gained 0.8% to $331.07 and�Celgene (CELG) has risen 1.1% to $166.59. The�SPDR S&P Biotech ETF�(XBI) has advanced 0.6% to $153.43.

5 Best Building Product Stocks To Buy For 2015: Questerre Energy Corp (QEC)

Questerre Energy Corporation (Questerre) is engaged in the exploration for, and the development, production and acquisition of oil and gas projects, particularly shale oil and gas. Questerre holds assets in British Columbia, Alberta, Saskatchewan, Manitoba and Quebec. Questerre has three core areas where it conducts the majority of its activity: Oil Shale Mining, Western Canada and the St. Lawrence Lowlands, Quebec. The Company has a 100% interest in two licenses covering approximately 100,000 acres in the Pasquia Hills area of east central Saskatchewan. The Antler area is approximately 200 kilometers from Regina in southeast Saskatchewan. The Vulcan area in Southern Alberta is prospective for natural gas and oil in multiple horizons. The Lowlands are situated in Quebec south of the St. Lawrence River between Montreal and Quebec City. As at December 31, 2011, the Company had an interest in 98 gross (55.2 net) producing and 40 gross (17.8 net) non-producing oil and natural gas. Advisors' Opinion:

• [By James E. Brumley]

  What do Questerre Energy Corp. (TSE:QEC) and Crescent Point Energy Corp. (TSE:CPG) know about oil in Saskatchewan that Centor Energy Inc. (OTCBB:CNTO) doesn't? Absolutely nothing. All three companies know there's oil in the southern part of the Canadian province, and they know exactly how to go get it. The only difference between QEC, CPG, and CNTO is, Questerre Energy and Crescent Point Energy are further along the development of their operations there than Centor Energy.

• [By John Udovich]

  While the Bakken formation is already on most investor radars,�few American investors may realize that the formation stretches North into the oil and gas rich Canadian province of Saskatchewan where�stocks like Surge Energy Inc (TSE: SGY), Questerre Energy Corp (TSE: QEC), Crescent Point Energy Corp (TSE: CPG), Keyera Corp (TSE: KEY) and Centor Energy Inc (OTCBB: CNTO) have been pumping out a good flow of newsworthy news in recent weeks. I should mention that Canada�� oil reserves are ranked #3 after to Venezuela and Saudi Arabia with over 95% of these reserves being the oil sands of Alberta while the neighboring province of Saskatchewan (which the Bakken formation stretches into from South Dakota and Montana) along with offshore areas of Newfoundland also contain substantial production and reserves (Note:�Excluding oil sands, Alberta would have 39% of Canada�� remaining conventional oil reserves,�followed by�offshore Newfoundland with�28% and Saskatchewan with 27%).

• [By James E. Brumley]

  Well, that answers that question. Questerre Energy Corp. (TSE:QEC) and Crescent Point Energy Corp. (TSE:CPG) likely knew they had some shale-oil mining neighbors in the Bakken Shale neighborhood in Saskatchewan, Canada, but they hadn't seen much of that competition. That's about to change soon. Adequately funded and eager to begin laying its final mining plans, Centor Energy Inc. (OTCBB:CNTO) is going to officially own 55% of a 21,000 acre shale oil property that's anywhere from just a few miles away to just a few meters away from and Crescent Point Energy's and Questerre Energy's operations in one of the oil-richest known areas in the Bakken formation. And to be clear, it's not like Centor Energy is just getting the ball rolling; the planning for this project has been underway for months. Once the property-acquisition deal is inked in mid-February, CNTO will likely finish up its feasibility study and begin the approval process for its facility later in the year. That's pretty quick, but as was noted, a great deal of the legwork has already been done.

5 Best Building Product Stocks To Buy For 2015: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Mylan (NASDAQ: MYL) got a boost, shooting up 2.49 percent to $51.10 on reports of interest in Sweden's Meda.

  IMS Health Holdings (NYSE: IMS) shares were also up, gaining 17.40 percent to $23.45 in their debut on the NYSE.